For the treatment of advanced ER+ breast cancer, several clinical trials have evaluated combinations of endocrine therapy and inhibitors of the PI3K/AKT/mTOR pathway, including mTOR inhibitors and dual PI3K/mTOR inhibitors [75]. The gene discussed is AKT1; the disease is breast cancer.